Silencing urokinase in the ventral tegmental area in vivo induces changes in cocaine-induced hyperlocomotion

Journal of Neurochemistry

Volumn 98, Issue 5, 2006, Pages 1619-1631

  Bahi, Amine ^a   Boyer, Frederic ^a   Kafri, Tal ^b   Dreyer, Jean Luc ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; In vivo gene transfer; Lentivirus; Plasticity; Small interfering RNA; Urokinase type plasminogen activator

Indexed keywords

COCAINE; DOXYCYCLINE; LENTIVIRUS VECTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PSYCHOSTIMULANT AGENT; SMALL INTERFERING RNA; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEARNING; LENTIVIRINAE; LOCOMOTION; MALE; MEMORY; NERVE CELL PLASTICITY; NERVOUS SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; VENTRAL TEGMENTUM;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, NORTHERN; CELL LINE; COCAINE; DOPAMINE UPTAKE INHIBITORS; DOXYCYCLINE; GENE EXPRESSION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MOTOR ACTIVITY; MUTAGENESIS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR; VENTRAL TEGMENTAL AREA;

ANIMALIA;

EID: 33746902770     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04013.x     Document Type: Article

References (67)

1. Ang E., Chen J., Zagouras P., Magna H., Holland J., Schaeffer E. and Nestler E. J. (2001) Induction of nuclear factor-κB in nucleus accumbens by chronic cocaine administration. J. Neurochem. 79, 221-224.
2. Bahi A., Boyer F., Gumy C., Kafri T. and Dreyer J. L. (2004a) In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioral changes in chronic cocaine administration. Eur. J. Neurosci. 20, 3473-3488.
3. Bahi A., Boyer F., Kafri T. and Dreyer J. L. (2004b) CD81-induced behavioral changes during chronic cocaine administration: in vivo gene delivery with regulatable lentivirus. Eur. J. Neurosci. 19, 1621-1633.
4. 3-receptor in the nucleus accumbens shell in vivo induces behavioral changes in cocaine-induced hyperlocomotion. Eur. J. Neurosci. 21, 3415-3426.
5. Bahi A., Boyer F., Kolira M. and Dreyer J. L. (2005b) In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. J. Neurochem. 92, 1243-1255.
6. Bednarski E. C., Ribak G. and Lynch G. (1997) Suppression of cathepsins B and L causes a proliferation of lysosomes and the formation of meganeurites in hippocampus. J. Neurosci. 17, 4006-4021.
7. 2+ influx and neurite growth in response to purified N-cadherin and laminin. J. Cell Biol. 127, 1461-1475.
8. de Bock C. E. and Wang Y. (2004) Clinical signifiance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 24, 13-39.
9. Calabresi P., Napolitano M., Centonze D., Marfia G. A., Gubellini P., Teule M. A., Berretta N., Bernardi G., Frati L. and Tolu M. (2000) Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur. J. Neurosci. 12, 1002-1012.
10. Del Bigio M. R., Hosain S. and Altumbabic M. (1999) Localization of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse forebrain during postnatal development. Int. J. Dev. Neurosci. 17, 387-399.
11. Deng G., Curriden S. A., Wang S., Rosenberg S. and Loskutoff D. J. (2003) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1563-1571.
12. Dent M. A., Sumi Y., Morris R. J. and Seeley P. J. (1993) Urokinase-type plasminogen activator expression by neurons and oligodendrocytes during process outgrowth in developing rat brain. Eur. J. Neurosci. 5, 633-647.
13. Evans D. M. and Sloan-Stakleff K. (2000) Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Am. Surg. 66, 460-464.
14. 1-receptor regulation of synaptic potentials in the ventral tegmental area after chronic drug treatment. Adv. Pharmacol. 42, 1002-1005.
15. Flumelli H., Jabaudon D., Magistretti P. J. and Martin J. L. (1999) BDNF stimulates expression, activity and release of tissue-type plasminogen activator in mouse cortical neurons. Eur. J. Neurosci. 11, 1639-1649.
16. Frey U., Muller M. and Kuhl D. A. (1996) A different form of long-lasting potentiation revealed in tissue plasminogen activator mutant mice. J. Neurosci. 16, 2057-2063.
17. Goldfinger L. E., Jiang L., Hopkinson S. B., Stack M. S. and Jones J. C. (2000) Spatial regulation and activity modulation of plasmin by high affinity binding to the G domain of the α3 subunit of laminin-5. J. Biol. Chem. 275, 34 887-34 893.
18. Iwata N., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iyo M., Sora I., Ujike H. and Ozaki N. (2004) No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: a collaborative study by the Japanese Genetics Initiative for Drug Abuse. Ann. NY Acad. Sci. 1025, 34-38.
19. Koob G. F., Sanna P. P. and Bloom F. E. (1998) Neuroscience of addiction. Neuron 21, 467-476.
20. Madani R., Hulo S., Toni N., Madani H., Steimer T., Muller D. and Vassalli J. D. (1999) Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J. 18, 3007-3012.
21. Masos T. and Miskin R. (1996) Localization of urokinase-type plasminogen activator mRNA in the adult mouse brain. Mol. Brain Res. 35, 139-148.
22. Mazzieri R., D'Alessio S., Kenmoe R. K., Ossowski L. and Blasi F. (2005) An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell (published online ahead of print).
23. McGuire P. G. and Seeds N. W. (1990) Degradation of underlying extracellular matrix by sensory neurons during neurite outgrowth. Neuron 4, 633-642.
24. Meiri N., Masos T., Rosenblum K., Miskin R. and Dudai Y. (1994) Overexpression of urokinase-type plasminogen activator in transgenic mice is correlated with impaired learning. Proc. Natl Acad. Sci., USA 91, 3196-3200.
25. Miskin R. and Abramovitz R. (2005) Enhancement of PAI-1 mRNA in cardiovascular cells after kainate injection is mediated through the sympathetic nervous system. J. Mol. Cell Cardiol. 38, 715-722.
26. Miskin R., Axelrod J. H., Griep A. E., Lee E., Belin D., Vassalli J. D. and Westphal H. (1990) Human and murine urokinase cDNAs linked to the αA-crystallin promoter exhibit lens and non-lens expression in transgenic mice. Eur. J. Biochem. 190, 31-38.
27. Moliterno D. J., Lange R. A., Gerard R. D., Willard J. E., Lackner C. and Hillis L. D. (1994) Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis. Am. J. Med. 96, 492-496.
28. Moonen G., Grau-Wagemans M. P. and Selak I. (1982) Plasminogen activator-plasmin system and neuronal migration. Nature 298, 753-755.
29. Nagai T., Yamada K., Yoshimura M., Ishikawa K., Miyamoto Y., Hashimoto K., Noda Y., Nitta A. and Nabeshima T. (2004) The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc. Natl Acad. Sci. USA 101, 3650-3655.
30. Nakajima K., Nagata K. and Kohsaka S. (1994) Plasminogen mediates an interaction between microglia and dopaminergic neurons. Eur. Neurol. 34, 10-16.
31. Nakagami Y., Saito H. and Matsuki N. (1997) Basic fibroblast growth factor and brain-derived neurotrophic factor promote survival and neuronal circuit formation in organotypic hippocampal culture. Jpn J. Pharmacol. 75, 319-326.
32. Nakagami Y., Abe K., Nishiyama N. and Matsuki N. (2000) Laminin degradation by plasmin regulates long-term potentiation. J. Neurosci. 20, 2003-2010.
33. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F. H., Verma I. M. and Trono D. (1996) In vivo gene delivery and stable transduction of non-dividing cells by a lentiviral vector. Science 272, 263-267.
34. Nestler E. J. (2001) Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2, 119-128.
35. Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E. T., Vivien D. and Buisson A. (2001) The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7, 59-64.
36. Oray S., Majewska A. and Sur M. (2004) Dendritic spine dynamics are regulated by monocular deprivation and extracellular matrix degradation. Neuron 44, 1021-1030.
37. Pang P. T., Teng H. K., Zaitsev E., Woo N. T., Sakata K., Zhen S. H., Teng K. K., Yung W. H., Hempstead B. L. and Lu B. (2004) Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306, 487-492.
38. Patton B. L., Chiu A. Y. and Sanes J. R. (1998) Synaptic laminin prevents glial entry into the synaptic cleft. Nature 393, 698-701.
39. Pawlak R., Melchor J. P., Matys T., Skrzypiec A. E. and Strickland S. (2005) Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc. Natl Acad. Sci. 102, 443-448.
40. Paxinos G. and Watson C. (1998) The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press, San Diego, USA.
41. Powell E. M., Mars W. M. and Levitt P. (2001) Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron 30, 79-89.
42. Ripley T. L., Rocha B. A., Oglesby M. W. and Stephens D. N. (1999) Increased sensitivity to cocaine, and over-responding during cocaine self-administration in tPA knockout mice. Brain Res. 826, 117-127.
43. Salle F. J. and Strickland S. (2002) Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J. Neurosci. 22, 2125-2134.
44. Sappino A. P., Madani R., Huarte J., Belin D., Kiss J. Z., Wohlwend A. and Vassalli J. D. (1993) Extracellular proteolysis in the adult murine brain. J. Clin. Invest 92, 679-685.
45. Seeds N. W., Basham M. E. and Haffke S. P. (1999) Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc. Natl Acad. Sci. USA 96, 14 118-14 123.
46. Sharon R., Abramovitz R. and Miskin R. (2002) Plasminogen mRNA induction in the mouse brain after kainate excitation: co-distribution with plasminogen activator inhibitor-2 (PAI-2) mRNA. Brain Res. Mol Brain Res. 104, 170-175.
47. Shimizu C., Yoshida S., Shibata M. et al. (1998) Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J. Biol. Chem. 273, 11 189-11 196.
48. Siconolfi L. B. and Seeds N. W. (2001) Induction of the plasminogen activator system accompanies peripheral nerve regeneration after sciatic nerve crush. J. Neurosci. 21, 4336-4347.
49. Sumi Y., Dent M. A., Owen D. E., Seeley P. J. and Morris R. J. (1992) The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. Development 116, 625-637.
50. Sunderland W. J., Son Y. J., Miner J. H., Sanes J. R. and Carlson S. S. (2000) The presynaptic calcium channel is part of a transmembrane complex linking a synaptic laminin (α4β2γ1) with non-erythroid spectrin. J. Neurosci. 20, 1009-1019.
51. Tarui T., Andronicos N., Czekay R. P., Mazar A. P., Bdeir K., Parry G. C., Kuo A., Loskutoff D. J., Cines D. B. and Takada Y. (2003) Critical role of integrin-5-1 in urokinase (uPA)-urokinase receptor (uPAR, CD87) signaling. J. Biol. Chem. 278, 29 863-29 872.
52. Todaro L. B., Ladeda V., Bal de Kier Joffe E. and Farias E. F. (2003) Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma. Oncol. Rep 10, 725-732.
53. Towle M. J., Lee A., Maduakor E. C., Schwartz C. E., Bridges A. J. and Littlefield B. A. (1993) Inhibition of urokinase by 4-substituted benzo[β]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res. 53, 2553-2559.
54. Tsirka S. E. (2002) Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem. Soc. Trans. 30, 222-225.
55. Tsirka S. E., Gualandris A., Amaral D. G. and Strickland S. (1995) Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377, 340-344.
56. Tsirka S. E., Rogove A. D., Bugge T. H., Degen J. L. and Strickland S. (1997) An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci. 17, 543-552.
57. Vassalli J.-D., Sappino A.-P. and Belin D. (1991) The plasminogen activator/plasmin system. J. Clin. Invest. 88, 1067-1072.
58. Wang G. J., Collinge M., Blasi F., Pardi R. and Bender J. R. (1998) Post-transcriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement. Proc. Natl Acad. Sci. USA 95, 6296-6301.
59. Wang Y., Dang J., Wang H., Allgayer H., Murrell G. A. C. and Boyd D. (2000) Identification of a novel nuclear factor-κB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur. J. Biochem. 267, 3248-3254.
60. Ware J. H., DiBenedetto A. J. and Pittman R. N. (1995) Localization of tissue plasminogen activator mRNA in the developing rat cerebellum and effects of inhibiting tissue plasminogen activator on granule cell migration. J. Neurobiol. 28, 9-22.
61. Werb Z. (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91, 439-442.
62. Wolfer D. P., Lang R., Cinelli P., Madani R. and Sonderegger P. (2001) Multiple roles of neurotrypsin in tissue morphogenesis and nervous system development suggested by the mRNA expression pattern. Mol. Cell Neurosci. 18, 407-433.
63. Wu Y. P., Siao C. H., Lu W. et al. (2000) The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J. Cell Biol. 148, 1296-1303.
64. Yamada K., Nagai T. and Nabeshima T. (2005) Drug dependence, synaptic plasticity, and tissue plasminogen activator. J. Pharmacol. Sci. 97, 157-161.
65. Yoshida S. and Shiosaka S. (1999) Plasticity-related serine proteases in the brain. Int. J. Mol Med. 3, 405-409.
66. Yu H., Schleuning W. D., Michl M., Liberatore G., Tan S. S. and Medcalf R. L. (2001) Control elements between -9.5 and -3.0 kb in the human tissue-type plasminogen activator gene promoter direct spatial and inducible expression to the murine brain. Eur. J. Neurosci. 14, 799-808.
67. Zhong M., Donna J. W., Minji J. and Steven L. G. (2001) Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J. Cell Sci. 114, 3387-3396.